Business Wire

DAWEX

9.6.2021 09:17:11 CEST | Business Wire | Press release

Share
Dawex Successfully Completes SOC 2 Type I and SOC 3 Security and Availability Audit Certification

Dawex , the leading data exchange and data marketplace technology company, today announced that it has successfully obtained the System and Organization Control (SOC) 2 Type I and SOC 3 certification. The completion of these examinations reinforces Dawex commitment to create and maintain the strictest controls to ensure the highest quality and security of services delivered to its customers.

SOC 2 Type I and SOC 3 are standards guaranteeing the implementation of internal controls for security, availability, processing integrity, confidentiality, or privacy. It also assesses and certifies the design of security processes and controls conducted by the organization. The SOC reports are awarded to Dawex to provide industry-wide recognition of conformity to stringent security standards, as set by the American Institute of Certified Public Accountants (AICPA).

“Dawex investment in security and compliance has always been our top priority. Data exchange requires, by its very nature, an advanced level of scrutiny regarding the control and safeguards we implement to protect and secure our infrastructure and the solutions delivered to our customers.” says Laurent Lafaye, co-CEO at Dawex. “The SOC 2 Type I & SOC 3 examination audits demonstrate our measures are aligned with worldwide industry standards and best practices of security and availability.”

Conducted by an independent third-party, the Dawex examination reports demonstrate to organizations and auditors how the company achieves key compliance controls and objectives, building trust and confidence in Dawex technologies. The requirements and security measures are constantly monitored, evaluated, and updated to reflect changing needs and offer the safest environment for conducting business.

“As organizations increasingly adopt data exchange technology, it's essential that we help businesses achieve and maintain compliance with their own frameworks." says Fabrice Tocco, co-CEO at Dawex. "Building on our commitment to deliver secure data exchanges, Dawex strives to exceed the highest standards for privacy and security, demonstrate the resiliency of our processes and instill confidence among our customers with transparency."

The Service Auditors’ Report, issued on May 28, 2021, provides a detailed description of Dawex controls, security processes and an independent assessment of whether the controls are placed in operation and suitably designed. To learn more and receive a copy of the report, click here .

About Dawex

Dawex is the leading data exchange and data marketplace technology company. Dawex mission is to facilitate and accelerate secure data circulation between economic stakeholders, institutions and private organizations, contributing to the development of the data economy. Awarded Technology Pioneer by the World Economic Forum, Dawex is a member of GAIA-X and a co-founding member of the Data Exchange Association . Created in 2015, Dawex has offices in France and Canada, expanding business operations to Asia, North America, and the Middle East.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 11:15:00 CEST | Press release

The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity. HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026061293689

Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release

Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of

Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release

The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release

AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye